Meeting the needs for pre-filtration and clarification of various aqueous solution samples! Ensuring non-heating and biological safety.
The "Acrodisc Syringe Filter - Versapor Membrane" can meet the needs for pre-filtration and clarification of various aqueous solution samples. It features a durable membrane that is flexible regardless of wet or dry conditions. It guarantees non-heat generation and biological safety. It is effective for pre-filtration of samples containing many fine particles, serum filtration, and dissolution tests, protecting equipment from particle accumulation. 【Features】 ■ Meets the needs for pre-filtration and clarification of various aqueous solution samples ■ Durable membrane with flexibility regardless of wet or dry conditions ■ Guarantees non-heat generation and biological safety *For more details, please refer to the PDF document or feel free to contact us.
Inquire About This Product
basic information
【Specifications (Partial)】 ■ Material Composition ・Filter Media: Versapor (hydrophilic acrylic copolymer with non-woven fabric support) ・Housing: Modified acrylic ■ Effective Filtration Area: 2.8 cm² ■ Inlet/Outlet Connection Type ・Inlet: Female Luer Lock ・Outlet: Male Luer Slip ■ Standard Residual Volume (after air purge): 50 μL or less ■ Maximum Operating Temperature: 55℃ *For more details, please refer to the PDF document or feel free to contact us.
Price range
Delivery Time
Applications/Examples of results
【Application】 ■Effective for pre-filtration of samples containing many fine particles, serum filtration, and dissolution tests. ■Protects equipment from the accumulation of fine particles. *For more details, please refer to the PDF document or feel free to contact us.
Company information
Cytiva and Pall Life Sciences have merged their businesses and will officially launch under the "Cytiva" brand on May 1, 2023. Under our mission of "Advancing therapies, faster," we will integrate both organizations and focus even more on supporting the development and manufacturing of better therapies for patients as a stronger global provider of technologies and services. The new Cytiva will offer a broader and deeper expertise and a rich lineup of products and services to better support various customers involved in research and the manufacturing and development of biopharmaceuticals, enabling them to deliver therapies to patients more quickly, from discovery to delivery. With a rich history spanning several hundred years, Pall Life Sciences and Cytiva, as part of the Danaher Group, will continue to unite to provide better services to our customers.